07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

A&G, Mayo Clinic deal

A&G granted the clinic worldwide, non-exclusive rights to patents and antibody reagents for the detection and measurement of progranulin ( PGRN ; PCDGF ) in blood. Mayo said it plans to offer a test by...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Financial News

Cellerix completes venture financing

Cellerix S.A. , Madrid, Spain   Business: Autoimmune, Dermatology, Gene/Cell therapy   Date completed: 11/11/09   Type: Venture financing   Raised: €27 million ($40.4 million)   Investors: Ysios Capital Partners; LSP-Life Sciences Partners; Ventech; Bankinter;...
01:10 , Nov 12, 2009 |  BC Extra  |  Financial News

Cellerix raises EUR 27 million

Cellerix S.A. (Madrid, Spain) raised EUR 27 million ($40.4 million) in a first close of a financing co-led by existing investors Ysios Capital Partners; Life Sciences Partners; and Ventech. New investors Bankinter; Capital Riesgo Madrid;...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

A&G, Celltrion deal

Celltrion will manufacture preclinical and clinical batches of A&G's anti-GP88 monoclonal antibody, which is in preclinical development for cancer. Also, Celltrion received exclusive commercialization rights to the antibody in Asia. A&G retains commercialization rights elsewhere....
08:00 , Mar 1, 2004 |  BC Week In Review  |  Company News

A&G, MedImmune Inc. other research news

Researchers published in Clinical Cancer Research that higher levels of PCDGF are expressed in invasive prostate cancer tissue than in benign or normal tissue. MEDI expects to file an IND for a compound targeting PCDGF...
07:00 , Sep 3, 2002 |  BioCentury  |  Strategy

Back to School: The Sweet Spot

Enough of gloom and doom. This year's Back to School issue leaves aside all thoughts of the stock market and instead focuses on what in the end is really important: strategies for building very small...
07:00 , Apr 22, 2002 |  BC Week In Review  |  Company News

A&G, MedImmune Inc., Panacea Pharmaceuticals deal

MEDI said HAAH is over-expressed in primary tumor tissues, including cancers of the pancreas, breast, ovary, liver, colon, prostate, lung, brain and bile duct. MEDI also said PCDGF is expressed by breast cancer cells that...
07:00 , Apr 19, 2002 |  BC Extra  |  Company News

MedImmune in-licenses 2 cancer technologies

MEDI received exclusive worldwide rights to two cancer technologies: Human Aspartyl (Asparaginyl) Beta-Hydroxylase (HAAH) enzyme targeting technology from Panacea (Rockville, Md.) and technology targeting PC-cell-derived growth factor (PCDGF) from A&G Pharmaceutical (Baltimore, Md.). MEDI made...